LFCR (Lifecore Biomedical) Tax Provision : $-0.1 Mil (TTM As of Aug. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Tax Provision?

Lifecore Biomedical's tax provision for the three months ended in Aug. 2024 was $0.0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Aug. 2024 was $-0.1 Mil.

Lifecore Biomedical Tax Provision Historical Data

The historical data trend for Lifecore Biomedical's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Tax Provision Chart

Lifecore Biomedical Annual Data

Trend

May15

May16

May17

May18

May19

May20

May21

May22

May23

May24

Tax Provision

Get a 7-Day Free Trial

8.77

6.35

5.21

-0.31

-0.18

Lifecore Biomedical Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
Tax Provision	Get a 7-Day Free Trial															-0.09	0.07	-0.22	0.06	0.03

Lifecore Biomedical Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.1 Mil.

Lifecore Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website

https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Executives

Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Christopher S Kiper	director	12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Raymond T. White	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Raymond H Diradoorian	director	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter	director	C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg	officer: Chief Financial Officer	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles	director	CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall	officer: Executive Vice President	3515 LYMAN BLVD., CHASKA MN 55318